{
    "root": "12bdbbc9-fbb0-4a0a-9147-37df8ac5dc5e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "clindamycin phosphate",
    "value": "20250228",
    "ingredients": [
        {
            "name": "CLINDAMYCIN PHOSPHATE",
            "code": "EH6D7113I8"
        },
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "clindamycin phosphate sodium chloride injection contains clindamycin , lincosamide antibacterial indicated treatment following adult pediatric patients appropriate dosing formulation achieved : • serious infections caused susceptible anaerobic bacteria ( 1.1 ) • infections due susceptible isolates streptococci , pneumococci staphylococci . ( 1.2 ) • lower respiratory tract infections . ( 1.3 ) • skin skin structure infections . ( 1.4 ) • gynecological infections . ( 1.5 ) • intra-abdominal infections . ( 1.6 ) • septicemia . ( 1.7 ) • bone joint infections . ( 1.8 ) limitation since clindamycin diffuse adequately cerebrospinal fluid , clindamycin phosphate sodium chloride injection used treatment meningitis ( 1.9 ) usage reduce development drug-resistant bacteria maintain effectiveness clindamycin phosphate sodium chloride injection antibacterial drugs , clindamycin phosphate sodium chloride injection used treat prevent infections proven strongly suspected caused susceptible bacteria . ( 1.10 )",
    "contraindications": "• dose clindamycin phosphate sodium chloride injection required equal 300 mg 600 mg 900 mg , product recommended alternative formulation clindamycin considered . ( 2.1 ) • recommended adult : serious infections due aerobic gram-positive cocci susceptible anaerobes ( generally including bacteroides fragilis , peptococcus species clostridioides species clostridium perfringens ) : 600–1200 mg/day 2 , 3 4 equal doses intravenous infusion . ( 2.2 ) • severe infections , particularly due proven suspected bacteroides fragilis , peptococcus species , clostridium species clostridium perfringens : 1200–2700 mg/day 2 , 3 4 equal doses intravenous infusion . ( 2.2 ) • pediatric patients ( 1 month age 16 years ) : 20 40 mg/kg/day 3 4 equal doses intravenous infusion . ( 2.3 ) • alternative pediatric patients dosing : 350 mg/m 2 /day serious infections 450 mg/m2/day severe infections . ( 2.3 ) • neonates ( less 1 month age ) : 15 20 mg/kg/day 3 4 equal doses intravenous infusion . ( 2.3 )",
    "warningsAndPrecautions": "clindamycin phosphate sodium chloride injection clear , colorless sterile solution intravenous infusion . 50 ml clindamycin phosphate sodium chloride injection , 300 mg/50 ml , 600mg/50ml , 900 mg/50 ml , contains 300 mg , 600 mg , 900 mg clindamycin , respectively ( clindamycin phosphate , usp ) 0.9 % sodium chloride solution . clindamycin phosphate sodium chloride injection single-dose galaxy containers available follows : 2g3455 twenty-four ( 24 ) -300 mg/50 ml containers ndc 0338-9545-24 2g3456 twenty-four ( 24 ) -600 mg/50 ml containers ndc 0338-9549-24 2g3457 twenty-four ( 24 ) -900 mg/50 ml containers ndc 0338-9553-24 exposure pharmaceutical products , including clindamycin phosphate sodium chloride , heat minimized . recommended galaxy plastic containers stored 20°c 25°c ( 68°f 77°f ) excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . avoid temperatures 30°c .",
    "adverseReactions": "clindamycin phosphate sodium chloride injection contraindicated individuals history hypersensitivity preparations containing clindamycin lincomycin .",
    "indications_original": "Clindamycin Phosphate in Sodium Chloride Injection contains clindamycin, a lincosamide antibacterial indicated for the treatment of the following in adult and pediatric patients for whom appropriate dosing with this formulation can be achieved: • Serious infections caused by susceptible anaerobic bacteria  ( 1.1 ) • Infections Due to Susceptible Isolates of Streptococci, Pneumococci and Staphylococci.  ( 1.2 ) • Lower Respiratory Tract Infections.  ( 1.3 ) • Skin and Skin Structure Infections.  ( 1.4 ) • Gynecological Infections.  ( 1.5 ) • Intra-abdominal Infections.  ( 1.6 ) • Septicemia.  ( 1.7 ) • Bone and Joint Infections.  ( 1.8 ) Limitation of use Since clindamycin does not diffuse adequately into the cerebrospinal fluid, Clindamycin Phosphate in Sodium Chloride Injection should not be used in the treatment of meningitis ( 1.9 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clindamycin Phosphate in Sodium Chloride Injection and other antibacterial drugs, Clindamycin Phosphate in Sodium Chloride Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.  ( 1.10 )",
    "contraindications_original": "• If a dose of Clindamycin Phosphate in Sodium Chloride Injection is required that does not equal 300 mg 600 mg or 900 mg, this product is not recommended for use and an alternative formulation of clindamycin should be considered.  ( 2.1 ) • Recommended Adult Dosage:  Serious infections due to aerobic gram-positive cocci and the more susceptible anaerobes (NOT generally including Bacteroides fragilis , Peptococcus species and Clostridioides species other than Clostridium perfringens ):  600–1200 mg/day in 2, 3 or 4 equal doses by intravenous infusion.  ( 2.2 ) • More severe infections, particularly those due to proven or suspected Bacteroides fragilis , Peptococcus species, or Clostridium species other than Clostridium perfringens :  1200–2700 mg/day in 2, 3 or 4 equal doses by intravenous infusion.  ( 2.2 ) • Dosage in Pediatric Patients (1 Month of Age to 16 Years):  20 to 40 mg/kg/day in 3 or 4 equal doses by intravenous infusion.  ( 2.3 ) • Alternative Pediatric Patients Dosing:  350 mg/m 2 /day for serious infections and 450 mg/m2/day for more severe infections.  ( 2.3 ) • Dosage in Neonates (Less than 1 Month of Age):  15 to 20 mg/kg/day in 3 to 4 equal doses by intravenous infusion.  ( 2.3 )",
    "warningsAndPrecautions_original": "Clindamycin Phosphate in Sodium Chloride Injection is a clear, colorless and sterile solution for intravenous infusion. Each 50 mL of Clindamycin in Phosphate in Sodium Chloride Injection, 300 mg/50 mL, 600mg/50mL, and 900 mg/50 mL, contains 300 mg, 600 mg, or 900 mg clindamycin, respectively (as clindamycin phosphate, USP) in 0.9% sodium chloride solution. Clindamycin in Phosphate in Sodium Chloride Injection in single-dose GALAXY containers is available as follows:\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              2G3455\n                           \n                           \n                              Twenty-four (24)-300 mg/50 mL containers\n                           \n                           \n                              NDC 0338-9545-24\n                           \n                        \n                        \n                           \n                              2G3456\n                           \n                           \n                              Twenty-four (24)-600 mg/50 mL containers\n                           \n                           \n                              NDC 0338-9549-24\n                           \n                        \n                        \n                           \n                              2G3457\n                           \n                           \n                              Twenty-four (24)-900 mg/50 mL containers\n                           \n                           \n                              NDC 0338-9553-24\n                           \n                        \n                     \n                  \n                  Exposure of pharmaceutical products, including clindamycin phosphate in sodium chloride, to heat should be minimized.  It is recommended that GALAXY plastic containers be stored at 20°C to 25°C (68°F to 77°F) excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].  Avoid temperatures above 30°C.",
    "adverseReactions_original": "Clindamycin Phosphate in Sodium Chloride Injection is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin."
}